SecBot SecBot
8-K ·Filed Aug 28, 2026

CYTK

CYTOKINETICS INC
BULLISH
Impact 7/10
Horizonmonths Processed2mo ago SEC0001193125-26-372456
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

This is a transformative pipeline event that de-risks the nHCM opportunity and supports peak sales estimates well above current consensus. Watch for FDA acceptance of the sNDA and potential accelerated review given the unmet need. The safety signal (LVEF <50%) is manageable but will require monitoring in the label.

DirectionBullish
Confidencehigh
Horizonmonths

MYQORZO

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
Next catalyst
None dated

What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$72.09
T+0 close · Aug 28, 2026 · via day close
Latest settled
−8.23%
T+20 · $66.16 · next T+60 in 6d
Vs SPY
−8.49%
α at T+20
Latest observation
−16.42%
T+54 · FF3 residual α
  1. T+0 · Aug 28 $72.09entry
  2. T+1 · 3mo ago −1.64%α −1.34% · $70.91
  3. T+5 · 2mo ago +0.87%α +0.76% · $72.72
  4. T+20 · 7w ago −8.23%α −8.49% · $66.16
  5. T+55 · todayOpen
  6. T+60 · in 6d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics announced positive Phase 3 results from ACACIA-HCM, the first-ever successful trial in non-obstructive HCM. The trial met both dual primary endpoints with statistical significance, and the company plans to submit a supplemental New Drug Application to the FDA in Q4 2026. This expands the potential label for aficamten (MYQORZO) from obstructive to the full spectrum of symptomatic HCM, representing a major pipeline catalyst.

Key Facts

  • ACACIA-HCM met both dual primary endpoints: KCCQ-CSS (p=0.021) and pVO2 (p=0.003) at Week 36 vs placebo
  • Supplemental NDA for aficamten in non-obstructive HCM to be submitted to FDA in Q4 2026
  • Results presented at ESC Congress 2026 and simultaneously published in the New England Journal of Medicine
  • Aficamten is already approved as MYQORZO for obstructive HCM in the U.S., China, EU, and UK
  • LVEF <50% occurred in 10.5% of aficamten patients vs 0.8% on placebo; serious adverse events 20.2% vs 14.7%

Financial Impact

Potential label expansion to cover ~50% of HCM patients (non-obstructive population), doubling the addressable market for aficamten

revenuemarket share

Risk Factors

  • FDA may require additional data or raise concerns about the LVEF <50% safety signal (10.5% vs 0.8%)
  • Competition from other cardiac myosin inhibitors in development for nHCM
  • Commercial execution risk in expanding from oHCM to nHCM market

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-372456
Document: 0001193125-26-372456-index.html0001193125-26-372456
Document: 0001193125-26-372456.txt0001193125-26-372456

Track record

46 reports on CYTK

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026